// App-Quantinova.ai

SAT0337 (2018) : Biologic dmards and psoriatic arthritis in europe in 2016/2017: characteristics of patients starting tnf-inhibitors or ustekinumab in the ongoing psabio observational cohort study

Researchers

Presenter

  • L. Gossec

Principal Investigators

  • P. Athanassiou

  • P. Bergmans

  • K. de Vlam

  • E. Gremese

  • B. Joven-Ibáñez

  • T.V. Korotaeva

  • F. Lioté

  • M.T. Nurmohamed

  • P.P. Sfikakis

  • S. Siebert

  • P. Smirnov

  • E. Theander

  • J.S. Smolen

Medical Centers

  • Sorbonne Universites, Paris, France

  • St. Paul (Agios Pavlos) Hospital, Thessaloniki, Greece

  • Janssen-Cilag BV, Breda, Netherlands

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Policlinico atA. Gemelliat?, Catholic University of the Sacred Heart, Rome, Italy

  • University Hospital 12 de October, Madrid, Spain

  • VA Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia

  • Hopital Lariboisiere & University Paris Diderot, Paris, France

  • Amsterdam Rheumatology and Immunology Center, VU University Medical center, Amsterdam, Netherlands

  • University of Athens, Dental School, Athens, Greece

  • University of Glasgow,

  • Janssen Pharmaceutica NV, Moscow, Russian Federation

  • Janssen, Issy-Les-Moulineaux, France

  • Medical University of Vienna, Vienna, Austria

Locations

  • France

  • Greece

  • Netherlands

  • Belgium

  • Italy

  • Spain

  • Russia

  • United Kingdom

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • NA

Study Id's

  • NCT02627768

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved